Froese Grant has recently filed a Form 3, revealing significant ownership interests in Helus Pharma Inc. This filing is critical as it highlights Grant's direct and indirect holdings in the pharmaceutical company, which may indicate a strategic alignment or investment in the sector.
Froese Grant operates as an entity within the financial landscape, with its recent filing dated October 23, 2026. The company is associated with Helus Pharma Inc., which is classified under the pharmaceutical preparations industry. This sector is known for its competitive nature, and any shifts in ownership can impact market dynamics.
The filing specifies that Froese Grant holds a total of 161,263 common shares in Helus Pharma Inc., with 5,263 shares held directly and 156,000 shares held through Greywolf Management Services Inc., a corporation owned and controlled by Grant. Additionally, the filing includes details about warrants that Grant possesses, which could further influence his stake in the company.
This disclosure could have implications for various stakeholders, including investors, analysts, and competitors within the pharmaceutical preparations sector. The ownership structure may provide insights into potential future strategies or collaborations involving Helus Pharma Inc.
Details were not available in the SEC filing regarding any upcoming actions or events related to this ownership disclosure. However, the filing does indicate that Froese Grant is actively engaged with Helus Pharma, which may lead to further developments in the future.